Polymyxin B is a lipopeptide antibiotic isolated from Bacillus polymyxa. Its basic structure consists of a polycationic peptide ring and a tripeptide side chain with a fatty acid tail. Polymyxin B is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 and B2 being the two major components. Polymyxin B acts on Gram-negative bacteria by interacting with lipopolysaccharide (LPS) of the outer membrane and destabilizing it. Polymyxin B is indicated for the treatment of many bacterial diseases such as meningeal infections, urinary tract infections and bacteremia.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q28824 Gene ID: 338037.0 Gene Symbol: MYLK Target Organism: Bos taurus (Bovine) |
70.0 µM [IC50] | ||
Target ID: Protein kinase C (Bos taurus) |
4.0 µM [IC50] | ||
Target ID: Na,K-ATPase (rat) |
800.0 µM [IC50] | ||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
|||
| Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
|||
| Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
|||
| Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| COMPARISON OF THE ACTION OF STREPTOMYCIN, POLYMYXIN B, AUREOMYCIN AND CHLOROMYCETIN ON H. PERTUSSIS, H. PARAPERTUSSIS, H. INFLUENZAE AND FIVE ENTERIC STRAINS OF GRAM-NEGATIVE BACILLI. | 1949 Sep |
|
| LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E. | 1949 Sep |
|
| CHEMICAL STUDIES ON POLYMYXIN B. | 1949 Sep |
|
| Pharmacokinetics of intravenous polymyxin B in critically ill patients. | 2008 Nov 15 |
|
| Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. | 2008 Oct |
|
| Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. | 2008 Oct |
|
| Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria. | 2015 Nov 13 |
|
| Polymyxin B Nephrotoxicity: From Organ to Cell Damage. | 2016 |
|
| Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. | 2016 Dec |
|
| Successful treatments with polymyxin B hemoperfusion and recombinant human thrombomodulin for fulminant Clostridium difficile-associated colitis with septic shock and disseminated intravascular coagulation: a case report. | 2016 Dec |
|
| The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe Pseudomonas aeruginosa pneumonia. | 2016 Dec |
|
| A feed-forward loop between SroC and MgrR small RNAs modulates the expression of eptB and the susceptibility to polymyxin B in Salmonella Typhimurium. | 2016 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: 25,000 to 30,000 units/kg/day (Intramuscular injection), 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks (Intrathecal injection).
15,000 to 25,000 units/kg body weight/day
Route of Administration:
Intravenous
Polymyxin B MICs were determined for different strains of P. aeruginosa in Ca-MHB using a broth macrodilution method. The MIC was defined as the lowest concentration of drug that resulted in no visible growth after 24 h of incubation at 35°C in ambient air. The polymyxin B MIC ranged from 0.5 to 1 mg/liter.
| Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Dec 15 15:50:08 GMT 2023
by
admin
on
Fri Dec 15 15:50:08 GMT 2023
|
| Record UNII |
19371312D4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 333.120
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
||
|
NCI_THESAURUS |
C78160
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1201283
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
SUB03938MIG
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
215-774-7
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
19371312D4
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
1547007
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
757278
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
1405-20-5
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
DTXSID5045839
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
388
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
19371312D4
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
m8963
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00781
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY | |||
|
C61895
Created by
admin on Fri Dec 15 15:50:08 GMT 2023 , Edited by admin on Fri Dec 15 15:50:08 GMT 2023
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
